New Development in Rare Pediatric Epilepsy: Biocodex Announces the Development of DIACOMIT® (stiripentol) Oral Suspension, a New Formulation to Aid in the Treatment of Dravet Syndrome in Young Children

BEDMINSTER, N.J., Nov. 14, 2024 /PRNewswire/ — The global pharmaceutical company, Biocodex, a long-time pioneer in the treatment of rare pediatric diseases, is proud to announce they are developing a new oral-suspension formulation for DIACOMIT, an FDA-approved treatment indicated for…